Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui
Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s
The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.
